Please login to the form below

Not currently logged in
Email:
Password:

Larry Bell joins Dutch biopharma Prosensa

Takes up role as head of global regulatory affairs

Prosena Larry BellDutch biopharmaceutical company Prosensa Therapeutics has appointed Larry Bell as head of global regulatory affairs.

He joins the Leiden-based company with more than 18 years of regulatory affairs experience gained at companies that include Merck, Bristol-Myers Squibb, Aventis and Amgen.

Prior to setting up his own consultancy, his most recent role was as vice president and global head of regulatory affairs at GE Healthcare

For his new role at Prosensa, which focuses on RNA-modulating therapeutics for rare diseases with high unmet need, Bell will be based in the US and oversee the company's global regulatory activities.

Bell said: “This is a key time to be joining the Prosensa team. As the orphan drugs space grows in size and scope, there are many regulatory considerations that need to be addressed in order for new drugs to reach the patients that need them.

“I look forward to helping progress Prosensa's cutting-edge therapies through the regulatory process.”

18th February 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics